EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity

Alexander J Kwiatkowski, Jacob A Schulman, Hayden M Pagendarm iD, Lucinda E Pastora iD, John T Tossberg, Ruilin Zhang, Neil C Chada iD, Mia E Woodruff iD, Taylor L Sheehy iD, Karan Arora, John Karijolich, Thomas M Aune und 1 weitere

ACS Applied Materials & Interfaces · 10.09.2025 · 17 (36) · 50560-50572

DOI: 10.1021/acsami.5c16047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 28.08.2025. Verfasst von Alexander J Kwiatkowski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States. Hauptthemen laut MEDLINE: Nanoparticles, Adjuvants, Immunologic, Adjuvants, Vaccine, Immunogenicity, Vaccine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIBIB NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccine adjuvants stimulate innate immunity to enhance and shape adaptive immune responses. However, approved adjuvants typically elicit weak CD8+ T cell responses to protein- and peptide-based vaccines, motivating an investigation into the discovery and testing of new adjuvants. Unedited forms of endogenous Alu RNAs are sensed by pattern recognition receptors (PRRs) to trigger sterile inflammation, and therefore we hypothesized that synthetic Alu RNA molecules could be harnessed as vaccine adjuvants. To enhance their intracellular delivery, Alu RNA was copackaged with a model antigen into polymer nanoparticles that promoted endosomal escape of Alu RNA to the cytosol. Using this nanovaccine formulation, we found that Alu RNA activated antigen-presenting cells in vitro and in vaccine-site draining lymph nodes in vivo. Furthermore, we demonstrated that vaccine formulations containing Alu RNA as an adjuvant elicited comparable CD8+ T cell responses to those containing the common but highly heterogeneous RNA adjuvant PolyIC, and that this response protected mice from tumor challenge. Based on this, we further evaluated the antitumor efficacy of nanovaccine formulations containing Alu RNA adjuvants in mice with established tumors, again observing comparable responses to formulations containing PolyIC. Finally, we found that nanovaccines adjuvanted with Alu RNA could improve responses to anti-PD-1 immune checkpoint blockade in tumor-bearing mice. Overall, this study demonstrates that unedited Alu RNA coformulated with antigen in polymer nanoparticles can be harnessed as an effective vaccine adjuvant for stimulating CD8+ T cell responses with antitumor function and may offer a sequence-defined alternative to PolyIC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesAdjuvants, ImmunologicAdjuvants, VaccineImmunogenicity, VaccineRNAAlu ElementsCancer VaccinesAnimalsMiceCD8-Positive T-LymphocytesMice, Inbred C57BLFemaleHumans

Stichwörter der Autor:innen

A-to-I editingAlu RNAadjuvantendosomal escapenanoparticles

Substanzen

Adjuvants, ImmunologicAdjuvants, VaccineRNACancer Vaccines

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
  • Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.

ORCID-Profile: Hayden M Pagendarm, Lucinda E Pastora, Neil C Chada, Mia E Woodruff, Taylor L Sheehy, John T Wilson

Förderung

  • NIDDK NIH HHS
  • NIBIB NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Science Foundation Graduate Research Fellowship Program
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Kwiatkowski, A. J., Schulman, J. A., Pagendarm, H. M., Pastora, L. E., Tossberg, J. T., Zhang, R., Chada, N. C., Woodruff, M. E., Sheehy, T. L., Arora, K., Karijolich, J., Aune, T. M., & Wilson, J. T. (2025). Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity. ACS Applied Materials & Interfaces, 17(36), 50560-50572. https://doi.org/10.1021/acsami.5c16047

Vancouver

Kwiatkowski AJ, Schulman JA, Pagendarm HM, Pastora LE, Tossberg JT, Zhang R, et al. Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity. ACS Applied Materials & Interfaces. 2025;17(36):50560-50572. doi:10.1021/acsami.5c16047

BibTeX
@article{Kwiatkowski2025,
  author = {Kwiatkowski, Alexander J and Schulman, Jacob A and Pagendarm, Hayden M and Pastora, Lucinda E and Tossberg, John T and Zhang, Ruilin and Chada, Neil C and Woodruff, Mia E and Sheehy, Taylor L and Arora, Karan and Karijolich, John and Aune, Thomas M and Wilson, John T},
  title = {Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  volume = {17},
  number = {36},
  pages = {50560--50572},
  doi = {10.1021/acsami.5c16047}
}
Kostenlos starten →